New Drug Application Submission Best Practices

This guide outlines essential strategies for compiling a New Drug Application (NDA) submission effectively. It emphasizes the importance of establishing a well-vetted regulatory strategy as the foundation for the NDA process, highlighting that this strategy should be adaptable and informed by current regulations and scientific understanding. The document details the necessity of engaging a strong, cross-functional team with relevant expertise, as well as the significance of utilizing Type B meetings with the FDA to clarify objectives and expectations. It also discusses the creation and maintenance of a risk map to identify and mitigate potential project disruptions. Effective communication with stakeholders is presented as a critical component of the development process, with recommendations for a structured communication plan. Finally, the guide advises beginning with the end goal in mind, using the Common Technical Document (CTD) as a framework to ensure all necessary elements are addressed throughout the NDA preparation.